Combatting resistant enterococcal infections: a pharmacotherapy review

References

• Kaye D. Enterococci. Biologic and epidemiologic characteristics and in vitro susceptibility. Arch Intern Med. 1982;142(11):2006–2009.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. drug resistance, biggest threats. 2016[cited 2017 Oct 18]. Available from: https://www.cdc.gov/drugresistance/biggest_threats.html
   Google Scholar
• MacCallum W, Hastings TA. Case of acute endocarditis caused by micrococcus zymogenes (nov. spec) with a description of the microorganism. J Exp Med. 1899;521–532.
   PubMedGoogle Scholar
• Powers JH. Antimicrobial drug development- the past, the present, and the future. Clin Microbiol Infect. 2004;10(Suppl. 4):23–31.
   PubMed Web of Science ®Google Scholar
• Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the surgical infection society and the infectious diseases society of America. Clin Infect Dis. 2010;50(2):133–164.
   PubMed Web of Science ®Google Scholar
• Hollenbeck BL, Rice LB. Intrinsic and acquired resistance mechanisms in enterococcus. Virulence. 2012;3(5):421–433.
   PubMed Web of Science ®Google Scholar
• Gilmore M, Clewell D, Ike Y, et al., editors. Enterococci: from commensals to leading causes of drug resistant infection. In: Enterococcal Infection- Treatment and Antibiotic Resistance. Boston: Massachusetts Eye and Ear Infirmary; 2014. p. 123–165.
   Google Scholar
• Yim J, Smith JR, Rybak MJ. Role of combination antimicrobial therapy for vancomycin-resistant enterococcus faecium infections: review of the current evidence. Pharmacotherapy. 2017;37(5):579–592.
   PubMed Web of Science ®Google Scholar
• Zasowski EJ, Claeys KC, Lagnf AM, et al. Time is of the essence: the impact of delayed antibiotic therapy on patient outcomes in hospital-onset enterococcal bloodstream infections. Clin Infect Dis. 2016;62(10):1242–1250.
   PubMed Web of Science ®Google Scholar
• Chuang YC, Lin HY, Chen PY, et al. Effect of daptomycin dose on the outcome of vancomycin-resistant, daptomycin-susceptible enterococcus faecium bacteremia. Clin Infect Dis. 2017;64(8):1026–1034.
   PubMed Web of Science ®Google Scholar
• Munita JM, Bayer AS, Arias CA. Evolving resistance among gram-positive pathogens. Clin Infect Dis. 2015;61(Suppl 2):S48–57.
   PubMedGoogle Scholar
• Reyes K, Bardossy AC, Zervos M. Vancomycin-resistant enterococci: epidemiology, infection prevention, and control. Infect Dis Clin North Am. 2016;30(4):953–965.
   PubMed Web of Science ®Google Scholar
• Bonten MJM, Willems R, Weinstein RA. Vancomycin-resistant enterococci: why are they here, and where do they come from? Lancet Infect Dis. 2001;1(5):314–325.
   PubMedGoogle Scholar
• Sullivan A, Edlund C, Nord CE. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis. 2001;1(2):101–114.
   PubMedGoogle Scholar
• Patel R, Gallagher JC. Vancomycin-resistant enterococcal bacteremia pharmacotherapy. Ann Pharmacother. 2015;49(1):69–85.
   PubMed Web of Science ®Google Scholar
• Deshpande LM, Fritsche TR, Moet GJ, et al. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis. 2007;58(2):163–170.
   PubMed Web of Science ®Google Scholar
• Karlowsky JA, Walkty AJ, Baxter MR, et al. In vitro activity of oritavancin against gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2015. Diagn Microbiol Infect Dis. 2017;87(4):349–356.
   PubMed Web of Science ®Google Scholar
• Belley A, Arhin FF, Moeck G. Evaluation of oritavancin dosing strategies against vancomycin-resistant enterococcus faecium isolates with or without reduced susceptibility to daptomycin in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother. 2018;62(1):e01873-17.
   PubMed Web of Science ®Google Scholar
• Arhin FF, Seguin DL, Belley A, et al. In vitro stepwise selection of reduced susceptibility to lipoglycopeptides in enterococci. Diagn Microbiol Infect Dis. 2017;89(2):168–171.
   PubMed Web of Science ®Google Scholar
• Belley A, Lalonde-Seguin D, Arhin FF, et al. Comparative pharmacodynamics of single-dose oritavancin and daily high-dose daptomycin regimens against vancomycin-resistant enterococcus faecium isolates in an in vitro pharmacokinetic/pharmacodynamic model of infection. Antimicrob Agents Chemother. 2017;61(10):e01265–17.
   Web of Science ®Google Scholar
• Van Bambeke F. Lipoglycopeptide antibacterial agents in gram-positive infections: a comparative review. Drugs. 2015;75(18):2073–2095.
   PubMed Web of Science ®Google Scholar
• Scaglione F. Pharmacokinetic/pharmacodynamic (PK/PD) considerations in the management of gram-positive bacteraemia. Int J Antimicrob Agents. 2010;36(Suppl 2):S33–39.
   PubMedGoogle Scholar
• Jumah MTB, Vasoo S, Menon SR, et al. Pharmacokinetic/pharmacodynamic (PK/PD) determinants of vancomycin efficacy in Enterococcal bacteremia. Antimicrob Agents Chemother. 2017.
   Google Scholar
• Carreno JJ, Kenney RM, Lomaestro B. Vancomycin-associated renal dusfunction: where are we now? Pharmacotherapy. 2014;34(12):1259–1268.
   PubMed Web of Science ®Google Scholar
• Hayden MK, Trenholme GM, Schultz JE, et al. In vivo development of teicoplanin resistance in a VanB enterococcus faecium. J Infect Dis. 1993;167:1224–1227.
   PubMed Web of Science ®Google Scholar
• Jones RN, Biedenbach DJ, Johnson DM, et al. In vitro evaluation of BI 397, a novel glycopeptide antimicrobial agent. J Chemother. 2001;13(3):244–254.
   PubMed Web of Science ®Google Scholar
• Arias CA, Contreras GA, Murray BE. Management of multidrug-resistant enterococcal infections. Clin Microbiol Infect. 2010;16(6):555–562.
   PubMed Web of Science ®Google Scholar
• Lefort A, Saleh-Mghir A, Garry L, et al. Activity of LY333328 combined with gentamicin in vitro in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant enterococcus faecalis. Antimicrob Agents Chemother. 2000;44(11):3017–3021.
   PubMed Web of Science ®Google Scholar
• Moellering RC, Wennersten C, Weinberg AN. Studies on antibiotic synergism against enterococci. J Lab Clin Med. 1971;77(5):821–828.
   PubMed Web of Science ®Google Scholar
• Lopez P, Gavalda J, Martin MT, et al. Efficacy of teicoplanin-gentamicin given once a day on the basis of pharmacokinetics in humans for treatment of enterococcal experimental endocarditis. Antimicrob Agents Chemother. 2001;45(5):1387–1393.
   PubMed Web of Science ®Google Scholar
• Tam VHMP, Levine DP, Brandel SM, et al. Once-daily aminoglycoside in the treatment of enterococcus faecalis endocarditis:case report and review. Pharmacotherapy. 2000;20(9):4.
   Web of Science ®Google Scholar
• Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American heart association. Circulation. 2015;132(15):1435–1486.
   PubMed Web of Science ®Google Scholar
• Pankey G, Ashcraft D. In vitro synergy of telavancin and rifampin against enterococcus faecium resistant to both linezolid and vancomycin. Ochsner J. 2013;13:61–65.
   PubMedGoogle Scholar
• Smith JR, Yim J, Raut A, et al. Oritavancin combinations with beta-lactams against multidrug-resistant staphylococcus aureus and vancomycin-resistant enterococci. Antimicrob Agents Chemother. 2016;60(4):2352–2358.
   PubMed Web of Science ®Google Scholar
• Hellinger WC, Rouse MS, Rabadan PM, et al. Continuous intravenous versus intermittent ampicillin therapy of experimental endocarditis caused by aminoglycoside-resistant enterococci. Antimicrob Agents Chemother. 1992;36(6).
   PubMed Web of Science ®Google Scholar
• Nau R, Sorgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev. 2010;23(4):858–883.
   PubMed Web of Science ®Google Scholar
• Cole KA, Kenney RM, Perri MB, et al. Outcomes of aminopenicillin therapy for vancomycin-resistant Enterococcal urinary tract infections. Antimicrob Agents Chemother. 2015;59(12):7362–7366.
   PubMed Web of Science ®Google Scholar
• Lavoie SR, Wong ES, Coudron PE, et al. Comparison of ampicillin-sulbactam with vancomycin for treatment of experimental endocarditis due to a beta-lactamase- producing, highly gentamicin-resistant isolate of enterococcus faecalis. Antimicrob Agents Chemother. 1993;37(7):1447–1451.
   PubMed Web of Science ®Google Scholar
• Le T, Bayer AS. Combination antibiotic therapy for infective endocarditis. Clin Infect Dis. 2003;36:615–621.
   PubMed Web of Science ®Google Scholar
• Carrizosa J, Levison ME. Minimal concentrations of aminoglycoside that can synergize with penicillin in enterococcal endocarditis. Antimicrob Agents Chemother. 1981;20(3):405–409.
   PubMed Web of Science ®Google Scholar
• Fernandez-Hidalgo N, Almirante B, Gavalda J, et al. Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating enterococcus faecalis infective endocarditis. Clin Infect Dis. 2013;56(9):1261–1268.
   PubMed Web of Science ®Google Scholar
• Luther MK, Rice LB, LaPlante KL. Ampicillin in combination with ceftaroline, cefepime, or ceftriaxone demonstrates equivalent activities in a high-inoculum enterococcus faecalis infection model. Antimicrob Agents Chemother. 2016;60(5):3178–3182.
   PubMed Web of Science ®Google Scholar
• Tang HJ, Chen CC, Zhang CC, et al. In vitro efficacy of fosfomycin-based combinations against clinical vancomycin-resistant Enterococcus isolates. Diagn Microbiol Infect Dis. 2013;77(3):254–257.
   PubMed Web of Science ®Google Scholar
• Liao CH, Huang TY, Tsai HY, et al. In vitro synergy of ampicillin with gentamicin, ceftriaxone and ciprofloxacin against Enterococcus faecalis. Int J Antimicrob Agents. 2014;44(1):84–85.
   PubMed Web of Science ®Google Scholar
• Kelesidis T, Humphries R, Uslan DZ, et al. Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians. Clin Infect Dis. 2011;52(2):228–234.
   PubMed Web of Science ®Google Scholar
• Arias CA, Panesso D, McGrath DM, et al. Genetic basis for in vivo daptomycin resistance in enterococci. N Engl J Med. 2011;365:892–900.
   PubMed Web of Science ®Google Scholar
• Storm JC, Diekema DJ, Kroeger JS, et al. Daptomycin exposure precedes infection and/or colonization with daptomycin non-susceptible enterococcus. Antimicrob Resist Infect Control. 2012;1(1):19.
   PubMedGoogle Scholar
• Linder KE, Nicolau DP, Nailor MD. Predicting and preventing antimicrobial resistance utilizing pharmacodynamics: part I gram positive bacteria. Expert Opin Drug Metab Toxicol. 2016;12(3):267–280.
   PubMed Web of Science ®Google Scholar
• CLSI. Clinical and laboratory standards institute performance standards for antimicrobial susceptibility testing: 26th informational supplement, vol M100 S26. Wayne, PA: Clinical Laboratory Standards Institute; 2016.
   Google Scholar
• Reissier S, Saleh-Mghir A, Guerin F, et al. In vivo daptomycin efficacy against experimental vancomycin-resistant enterococcus faecium endocarditis. J Antimicrob Chemother. 2018.
   PubMed Web of Science ®Google Scholar
• Hall AD, Steed ME, Arias CA, et al. Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant enterococcus isolates in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother. 2012;56(6):3174–3180.
   PubMed Web of Science ®Google Scholar
• Shukla BS, Shelburne S, Reyes K, et al. Influence of minimum inhibitory concentration in clinical outcomes of enterococcus faecium bacteremia treated with daptomycin: is it time to change the breakpoint? Clin Infect Dis. 2016;62(12):1514–1520.
   PubMed Web of Science ®Google Scholar
• Berg ML, Estes LL, Dierkhising RA, et al. Evaluation of impact of statin use on development of CPK elevation during daptomycin therapy. Ann Pharmacother. 2014;48(3):320–327.
   PubMed Web of Science ®Google Scholar
• Smith JR, Barber KE, Raut A, et al. Beta-Lactams enhance daptomycin activity against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium in in vitro pharmacokinetic/pharmacodynamic models. Antimicrob Agents Chemother. 2015;59(5):2842–2848.
   PubMed Web of Science ®Google Scholar
• Sakoulas G, Rose W, Nonejuie P, et al. Ceftaroline restores daptomycin activity against daptomycin-nonsusceptible vancomycin-resistant enterococcus faecium. Antimicrob Agents Chemother. 2014;58(3):1494–1500.
   PubMed Web of Science ®Google Scholar
• Werth BJ, Barber KE, Tran KN, et al. Ceftobiprole and ampicillin increase daptomycin susceptibility of daptomycin-susceptible and -resistant VRE. J Antimicrob Chemother. 2015;70(2):489–493.
   PubMed Web of Science ®Google Scholar
• Luther MK, Arvanitis M, Mylonakis E, et al. Activity of daptomycin or linezolid in combination with rifampin or gentamicin against biofilm-forming enterococcus faecalis or E. faecium in an in vitro pharmacodynamic model using simulated endocardial vegetations and an in vivo survival assay using galleria mellonella larvae. Antimicrob Agents Chemother. 2014;58(8):4612–4620.
   PubMed Web of Science ®Google Scholar
• Hindler JA, Wong-Beringer A, Charlton CL, et al. In vitro activity of daptomycin in combination with beta-lactams, gentamicin, rifampin, and tigecycline against daptomycin-nonsusceptible enterococci. Antimicrob Agents Chemother. 2015;59(7):4279–4288.
   PubMed Web of Science ®Google Scholar
• Pankey G, Ashcraft D, Patel N. In vitro synergy of daptomycin plus rifampin against enterococcus faecium resistant to both linezolid and vancomycin. Antimicrob Agents Chemother. 2005;49(12):5166–5168.
   PubMed Web of Science ®Google Scholar
• Hall Snyder AD, Werth BJ, Nonejuie P, et al. Fosfomycin enhances the activity of daptomycin against vancomycin-resistant enterococci in an in vitro pharmacokinetic-pharmacodynamic model. Antimicrob Agents Chemother. 2016;60(10):5716–5723.
   PubMed Web of Science ®Google Scholar
• Bi R, Qin T, Fan W, et al. The emerging problem of linezolid-resistant enterococcus. J Glob Antimicrob Resist. 2017;13:11–19.
   PubMedGoogle Scholar
• Klupp EM, Both A, Belmar Campos C, et al. Tedizolid susceptibility in linezolid- and vancomycin-resistant enterococcus faecium isolates. Eur J Clin Microbiol Infect Dis. 2016;35(12):1957–1961.
   PubMed Web of Science ®Google Scholar
• Lee EY, Caffrey AR. Thrombocytopenia with linezolid and tedizolid. Antimicrob Agents Chemother. 2018;62(1):1–4.
   Web of Science ®Google Scholar
• Descourouez JL, Jorgenson MR, Wergin JE, et al. Fosfomycin synergy in vitro with amoxicillin, daptomycin, and linezolid against vancomycin-resistant Enterococcus faecium from renal transplant patients with infected urinary stents. Antimicrob Agents Chemother. 2013;57(3):1518–1520.
   PubMed Web of Science ®Google Scholar
• Taubert M, Zander J, Frechen S, et al. Optimization of linezolid therapy in the critically ill: the effect of adjusted infusion regimens. J Antimicrob Chemother. 2017;72(8):2304–2310.
   PubMed Web of Science ®Google Scholar
• Heintz BH, Halilovic J, Christensen CL. Vancomycin-resistant enterococcal urinary tract infections. Pharmacotherapy. 2010;30(11):1136–1149.
   PubMed Web of Science ®Google Scholar
• Fosfomycin [package insert]. Forest Pharmaceuticals. St. Louis, MO: Monurol (fosfomycin); 2011.
   Google Scholar
• Falagas ME, Vouloumanou EK, Samonis G, et al. Fosfomycin. Clin Microbiol Rev. 2016;29(2):321–347.
   PubMed Web of Science ®Google Scholar
• EUCAST. The European committee on antimicrobial susceptibility testing-EUCAST. Clinical breakpoints; 2017[cited 2017 Oct 11]. Available from: http://www.eucast.org/%5B
   Google Scholar
• Ou LB, Nadeau L. Fosfomycin susceptibility in multidrug-resistant enterobacteriaceae species and vancomycin-resistant enterococci urinary isolates. Can J Hosp Pharm. 2017;70(5):368–374.
   PubMed Web of Science ®Google Scholar
• Pontikis K, Pefanis A, Tsaganos T, et al. Efficacy of tigecycline alone and in combination with gentamicin in the treatment of experimental endocarditis due to linezolid-resistant Enterococcus faecium. Antimicrob Agents Chemother. 2013;57(7):3392–3394.
   PubMed Web of Science ®Google Scholar
• Erlandson KM, Sun J, Iwen PC, et al. Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant Enterococcus bacteremia. Clin Infect Dis. 2008;46(1):30–36.
   PubMed Web of Science ®Google Scholar
• Lin U, Bhusal Y, Horwitz D, et al. Less is more: overtreatment of enterococcal bacteriuria. Arch Intern Med. 2012;172(1):33–38.
   PubMedGoogle Scholar
• Shah KJ, Cherabuddi K, Shultz J, et al. Ampicillin for the treatment of complicated urinary tract infections caused by vancomycin-resistant enterococcus spp (VRE): a single-center university hospital experience. Int J Antimicrob Agents. 2018;51(1):57–61.
   PubMed Web of Science ®Google Scholar
• Neuner EA, Sekeres J, Hall GS, et al. Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms. Antimicrob Agents Chemother. 2012;56(11):5744–5748.
   PubMed Web of Science ®Google Scholar
• Huttner A, Kowalczyk A, Turjeman A, et al. Effect of 5-day nitrofurantoin vs single-dose fosfomycin on clinical resolution of uncomplicated lower urinary tract infection in women: a randomized clinical trial. JAMA. 2018;319(17):1781–1789.
   PubMed Web of Science ®Google Scholar
• Huttner B, Jones M, Huttner A, et al. Antibiotic prescription practices for pneumonia, skin and soft tissue infections and urinary tract infections throughout the US veterans affairs system. J Antimicrob Chemother. 2013;68(10):2393–2399.
   PubMed Web of Science ®Google Scholar
• Babinchak T, Ellis-Grosse E, Dartois N, et al. Safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of poold clinical trial data. Clin Infect Dis. 2005;41(Suppl 5):S354–S367.
   PubMed Web of Science ®Google Scholar
• McGovern PC, Wible M, El-Tahtawy A, et al. All-cause mortality imbalance in the tigecycline phase 3 and 4 clinical trials. Int J Antimicrob Agents. 2013;41(5):463–467.
   PubMed Web of Science ®Google Scholar
• Wang JS, Muzevich K, Edmond MB, et al. Central nervous system infections due to vancomycin-resistant enterococci: case series and review of the literature. Int J Infect Dis. 2014;25:26–31.
   PubMed Web of Science ®Google Scholar
• Knoll BM, Hellmann M, Kotton CN. Vancomycin-resistant enterococcus faecium meningitis in adults: case series and review of the literature. Scand J Infect Dis. 2013;45(2):131–139.
   PubMed Web of Science ®Google Scholar
• Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004;39:1267–1284.
   PubMed Web of Science ®Google Scholar
• Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 infectious diseases society of America’s clinical practice guidelines for healthcare-associated ventriculitis and meningitis. Clin Infect Dis. 2017.
   Google Scholar
• Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the infectious diseases society of America. Clin Infect Dis. 2009;49(1):1–45.
   PubMed Web of Science ®Google Scholar
• Bouza E, Kestler M, Beca T, et al. The NOVA score: a proposal to reduce the need for transesophageal echocardiography in patients with enterococcal bacteremia. Clin Infect Dis. 2015;60(4):528–535.
   PubMed Web of Science ®Google Scholar
• Fletcher JM, Kram SJ, Sarubbi CB, et al. Effectiveness of vancomycin or beta-lactam therapy in ampicillin-susceptible enterococcus spp. Bloodstream infections. J Pharm Pract. 2018;24:897190017751208.
   PubMedGoogle Scholar
• Foo H, Chater M, Maley M, et al. Glycopeptide use is associated with increased mortality in Enterococcus faecalis bacteraemia. J Antimicrob Chemother. 2014;69(8):2252–2257.
   PubMed Web of Science ®Google Scholar
• Raad I, Darouiche R, Vasquez J, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis. 2005;40:374–380.
   PubMed Web of Science ®Google Scholar
• Sandoe JAT. Enterococcal intravascular catheter-related bloodstream infection: management and outcome of 61 consecutive cases. J Antimicrob Chemother. 2002;50(4):577–582.
   PubMed Web of Science ®Google Scholar
• Beganovic M, Luther MK, Rice LB, et al. A review of combination antimicrobial therapy for enterococcus faecalis bloodstream infections and infective endocarditis. Clin Infect Dis. 2018.
   PubMedGoogle Scholar
• Osmon DR, Berbari EF, Berendt AR, et al. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the infectious diseases society of America. Clin Infect Dis. 2013;56(1):e1–e25.
   PubMed Web of Science ®Google Scholar
• Dahl A, Rasmussen RV, Bundgaard H, et al. Enterococcus faecalis infective endocarditis: a pilot study of the relationship between duration of gentamicin treatment and outcome. Circulation. 2013;127(17):1810–1817.
   PubMed Web of Science ®Google Scholar
• Bouza E, Valerio M, Soriano A, et al. Dalbavancin in the treatment of different gram-positive infections: a real-life experience. Int J Antimicrob Agents. 2018;51(4):571–577.
   Web of Science ®Google Scholar
• Moise PA, Sakoulas G, McKinnell JA, et al. Clinical outcomes of daptomycin for vancomycin-resistant enterococcus bacteremia. Clin Ther. 2015;37(7):1443–1453, e1442.
   PubMed Web of Science ®Google Scholar
• Casapao AM, Kullar R, Davis SL, et al. Multicenter study of high-dose daptomycin for treatment of enterococcal infections. Antimicrob Agents Chemother. 2013;57(9):4190–4196.
   PubMed Web of Science ®Google Scholar
• Britt NS, Potter EM, Patel N, et al. Comparative effectiveness and safety of standard-, medium-, and high-dose daptomycin strategies for the treatment of vancomycin-resistant enterococcal bacteremia among veterans affairs patients. Clin Infect Dis. 2017;64(5):605–613.
   PubMed Web of Science ®Google Scholar
• Smith TT, Tamma PD, Do TB, et al. Prolonged linezolid use is associated with the development of linezolid-resistant enterococcus faecium. Diagn Microbiol Infect Dis. 2018;91(2):161–163.
   Web of Science ®Google Scholar
• Wilcox MH, Tack KJ, Bouza E, et al. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis. 2009;48(2):203–212.
   PubMed Web of Science ®Google Scholar
• Birmingham MC, Rayner CR, Meagher AK, et al. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis. 2003;36(2):159–168.
   PubMed Web of Science ®Google Scholar
• Britt NS, Potter EM, Patel N, et al. Comparison of the effectiveness and safety of linezolid and daptomycin in vancomycin-resistant enterococcal bloodstream infection: a national cohort study of veterans affairs patients. Clin Infect Dis. 2015;61(6):871–878.
   PubMed Web of Science ®Google Scholar
• Chuang YC, Wang JT, Lin HY, et al. Daptomycin versus linezolid for the treatment of vancomycin-resistant enterococcal bacteremia: systematic review and meta-analysis. BMC Infect Dis. 2014;14(687):1–10.
   PubMedGoogle Scholar
• Zhao M, Liang L, Ji L, et al. Similar efficacy and safety of daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bloodstream infections: a meta-analysis. Int J Antimicrob Agents. 2016;48(3):231–238.
   PubMed Web of Science ®Google Scholar
• Whang DW, Miller LG, Partain NM, et al. Systematic review and meta-analysis of linezolid and daptomycin for treatment of vancomycin-resistant enterococcal bloodstream infections. Antimicrob Agents Chemother. 2013;57(10):5013–5018.
   PubMed Web of Science ®Google Scholar
• Balli EP, Venetis CA, Miyakis S. Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bacteremia. Antimicrob Agents Chemother. 2014;58(2):734–739.
   PubMed Web of Science ®Google Scholar
• Kullar R, Casapao AM, Davis SL, et al. A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis. J Antimicrob Chemother. 2013;68(12):2921–2926.
   PubMed Web of Science ®Google Scholar
• Menon V, Davis R, Shackel N, et al. Failure of daptomycin beta-lactam combination therapy to prevent resistance emergence in enterococcus faecium. Diagn Microbiol Infect Dis. 2018;90(2):120–122.
   PubMed Web of Science ®Google Scholar
• Sakoulas G, Bayer AS, Pogliano J, et al. Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant enterococcus faecium. Antimicrob Agents Chemother. 2012;56(2):838–844.
   PubMed Web of Science ®Google Scholar
• Tsigrelis C, Singh KV, Coutinho TD, et al. Vancomycin-resistant enterococcus faecalis endocarditis: linezolid failure and strain characterization of virulence factors. J Clin Microbiol. 2007;45(2):631–635.
   PubMed Web of Science ®Google Scholar
• Noskin GA, Siddiqui F, Stosor V, et al. Successful treatment of persistent vancomycin-resistant enterococcus faecium bacteremia with linezolid and gentamicin. Clin Infect Dis. 1999;28(3):689–690.
   PubMed Web of Science ®Google Scholar
• Johnson JA, Feeney ER, Kubiak DW, et al. Prolonged use of oritavancin for vancomycin-resistant Enterococcus faecium prosthetic valve endocarditis. Open Forum Infect Dis. 2015;2(4):ofv156.
   PubMedGoogle Scholar
• Foster RA, Philavong KP, Weissman S, et al. Oritavancin for the treatment of daptomycin non-susceptible vancomycin-resistant enterococci osteomyelitis. Infect Dis Clin Pract (Baltim Md). 2018;26(2):97–99.
   Web of Science ®Google Scholar
• Orbactiv (R) oritavancin [package insert]. Lincolnshire, IL: Melinta Therapeutics, Inc.; 2018.
   Google Scholar
• Lahey T, Shah R, Gittzus J, et al. Infectious diseases consultation lowers mortality from staphylococcus aureus bacteremia. Medicine (Baltimore). 2009;88(5):263–267.
   PubMed Web of Science ®Google Scholar
• ARLG. Studies in progress. Prospective evaluation of clinical outcomes of cancer patients with VRE bacteremia; 2017[cited 2018 Feb 27]. Avbailable from: https://arlg.org/studies-in-progress
   Google Scholar
• Timbrook TT, Morton JB, McConeghy KW, et al. The effect of molecular rapid diagnostic testing on clinical outcomes in bloodstream infections: a systematic review and meta-analysis. Clin Infect Dis. 2017;64(1):15–23.
   PubMed Web of Science ®Google Scholar